In his weekly clinical update, Dr. Griffin apprises us about the first case of highly pathogenic influenza in Canda, children dying of influenza infection and novel genetic reassortments of the virus, the Marburg virus outbreak in Rwanda, number of mpox infections, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, how scientific mistrust has affected COVID-19 vaccine administration, resolution of the FDA hold on Novovax’s combination influenza and COVID vaccine, where to find PEMGARDA, how Paxlovid SAVES you money, when to use steroids to treat COVID-19 and how trace amounts of cytokines elicted during SARS-CoV-2 infection negatively impact cardiac function.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Bird flu flew into British Columbia Canada (Global News Canada)
• H5N1 in British Columbia (CIDRAP)
• Highly Pathogenic Avian Influenza flies commercial and domestic (USDA)
• Countdown till the end of Marburg outbreak (WHO Rwanda)
• First kid’s death due to flu (CIDRAP)
• Influenza weekly surveillance report: clift notes (CDC FluView)
• H5N1 novel reassortments in migratory birds in China (Emerging Infectious Diseases)
• Serologic evidence of recent infection with highly pathogenic avian influenza A (MMWR)
• Seriously? 50,000 mpox cases in African outbreak (CIDRAP)
• Respiratory virus activity (CDC Respiratory Illnesses)
• COVID-19 deaths (CDC)
• COVID-19 national and regional trends (CDC)
• Waste water scan for 11 pathogens (WastewaterSCan)
• COVID-19 variant tracker (CDC)
• SARS-CoV-2 genomes galore (Nextstrain)
• Science trust: behind COVID 19 vaccine acceptance (Vaccine X)
• Vaccine mistrust levels are not budging (Healthday)
• FDA clinical hold lifted on Novavax’s combination COVID-flu vaccine(Reuters)
• Where to get pemgarda (Pemgarda)
• EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
• Fusion center near you….if in NY (Prime Fusions)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (ID Society)
• Drug interaction checker (University of Liverpool)
• Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir  (CMI: Clinical Microbiology and Infection)
• Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (CID)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (ID Society)
• What to do when sick with a respiratory virus (CDC)
• When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Secondary bacterial infection follows COVID-19 (Nature Communications)
• Daniel Griffin’s evidence based medical practices for long COVID (OFID)
• Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function (Nature Medicine)
• Letters read on TWiV 1166
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]